Nerlynx 40 mg FC tablets
PDF Leaflet Revision Date: 23 January 2026
Clinical Summary
Quick overview from the medicine insert
Indication
Extended adjuvant treatment of early-stage hormone receptor positive HER2-overexpressed breast cancer post-trastuzumab.
Dosage (summary)
240 mg (6 tablets) orally once daily with food for 1 year.
Special Populations
- Renal impairment
- Hepatic impairment
- Elderly
Pregnancy & Breastfeeding
May cause fetal harm; avoid during pregnancy and breastfeeding.
Key Drug Interactions
- Strong CYP3A4/P-gp inducers
- Strong CYP3A4/P-gp inhibitors
- Grapefruit and pomegranate
Contraindications
- Hypersensitivity to neratinib
- Severe hepatic impairment
- Strong/moderate CYP3A4/P-gp inducers
Common side effects
- Diarrhoea
- Nausea
- Fatigue
- Vomiting
- Abdominal pain
- Rash
Counselling Points
- Take with food
- Monitor for diarrhoea
- Use effective contraception during treatment
Serious warnings
- Severe diarrhoea
- Hepatotoxicity
- Cardiac monitoring in patients with risk factors
Important Disclaimer
The Nerlynx 40 mg FC tablets professional information leaflet below is the property of Key Oncologics and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
